Spectra for epochs of different vigilance states across the entire DP

Spectra for epochs of different vigilance states across the AC220 cancer entire DP (left hand) and LP (right hand). Solid lines denote means and shaded region around lines denotes SEM. A, Wake. B, NREM. C, REM. D-F, Change over the day in summated power in different frequency bandwidths from the power spectra: delta (left hand column), theta (middle column), and gamma (right hand column). D, Wake epochs. Left panel: For wake delta power, there was an overall Pleconaril site interaction (drug x time of day within photoperiod, F(12, 182.27) = 2.47, p = 0.005) and a secondary interaction (drug x photoperiod, F(2, 185.16) = 3.62, p = 0.029) with a main effect of photoperiod (F(1, 176.67) = 34.22, p < 0.001). Specifically, there was increased wake delta power during the first half of the dark photoperiod on the recovery day (ZT 12?8: t(191.85) ! 2.94, p 0.007). Middle panel: For wake theta power, there was an overall interaction (drug x time of day within photoperiod, F(12, 180.96) = 2.05, p = 0.022), but there were no pair-wise differences at any time point on either the drug or recovery days and vehicle. Right panel: No effect of AM3506 treatment on wake gamma power. E, NREM epochs. Left panel: For NREM delta power, there was an overall interaction (drug x time of day within photoperiod, F(12, 178.50) = 3.88, p < 0.001) with a main effect of photoperiod (F(1, 115.69) = 6.88, p = 0.010). On the recovery day, NREM delta was elevated at one point during the dark photoperiod (ZT 15?8: t(151.37) = 2.55, p = 0.024). Middle panel: No effect of AM3506 on NREM theta. Right panel: For NREM gamma power, there was a secondary interaction (drug x photoperiod, F(2, 185.23) = 3.54, p = 0.031) and a nested interaction (time of day within photoperiod, F(6, 180.37) = 8.35, p < 0.001) with a main effect of drug treatment SART.S23506 (F(2, 171.77) = 9.94, p < 0.001). Overall, AM3506 reduced NREM gamma (t(155.32) = -3.45, p = 0.001), and relative to vehicle, AM3506 specifically reduced NREM gamma across the first 18 Hr of the experiment (ZT 12?6: t(170.04) -2.42, p 0.033). F, REM epochs. Left panel: No effect of AM3506 on REM delta power. Middle panel: For REM theta, there was a significant overall interaction (drug x time of day within photoperiod, F(12, 157.56) = 1.96, p = 0.031) with a main effect of photoperiod (F(1, 104.31) = 6.78, p = 0.011). Compared to vehicle, REM theta was increased during the first 3 Hr immediately following administration of AM3506 (t(63.88) = 3.17, p = 0.005). Right j.jebo.2013.04.005 panel: For REM gamma power, there was an overall interaction (drug x time of day within photoperiod,PLOS ONE | DOI:10.1371/journal.pone.0152473 March 31,37 /Endocannabinoid Signaling Regulates Sleep StabilityF(12, 166.38) = 2.09, p = 0.020), a secondary interaction (drug x photoperiod, F(2, 172.23) = 3.29, p = 0.039) with main effects of drug (F(2, 148.36) = 8.64, p < 0.001) and photoperiod (F(1, 146.71) = 19.90, p < 0.001). Overall, REM gamma power was reduced following AM3506 administration (t(125.06) = -2.67, p = 0.017) with specific reduction in REM gamma during the first 9 Hr of the experiment (ZT 12?1: t(143.63) -3.10, p 0.005). Symbols/Bars represent mean EM for 3 Hr time bins (N = 9). Grey background in graphs shows dark photoperiod. Asterisks denote significant difference from vehicle baseline. All injections administered at onset of dark photoperiod (ZT 12:00). (PDF) S8 Fig. Power Spectral Features of EEG are Altered by Administration of the CB1 Antagonist AM281 Before the Dark Photoperiod. A--C, Po.Spectra for epochs of different vigilance states across the entire DP (left hand) and LP (right hand). Solid lines denote means and shaded region around lines denotes SEM. A, Wake. B, NREM. C, REM. D-F, Change over the day in summated power in different frequency bandwidths from the power spectra: delta (left hand column), theta (middle column), and gamma (right hand column). D, Wake epochs. Left panel: For wake delta power, there was an overall interaction (drug x time of day within photoperiod, F(12, 182.27) = 2.47, p = 0.005) and a secondary interaction (drug x photoperiod, F(2, 185.16) = 3.62, p = 0.029) with a main effect of photoperiod (F(1, 176.67) = 34.22, p < 0.001). Specifically, there was increased wake delta power during the first half of the dark photoperiod on the recovery day (ZT 12?8: t(191.85) ! 2.94, p 0.007). Middle panel: For wake theta power, there was an overall interaction (drug x time of day within photoperiod, F(12, 180.96) = 2.05, p = 0.022), but there were no pair-wise differences at any time point on either the drug or recovery days and vehicle. Right panel: No effect of AM3506 treatment on wake gamma power. E, NREM epochs. Left panel: For NREM delta power, there was an overall interaction (drug x time of day within photoperiod, F(12, 178.50) = 3.88, p < 0.001) with a main effect of photoperiod (F(1, 115.69) = 6.88, p = 0.010). On the recovery day, NREM delta was elevated at one point during the dark photoperiod (ZT 15?8: t(151.37) = 2.55, p = 0.024). Middle panel: No effect of AM3506 on NREM theta. Right panel: For NREM gamma power, there was a secondary interaction (drug x photoperiod, F(2, 185.23) = 3.54, p = 0.031) and a nested interaction (time of day within photoperiod, F(6, 180.37) = 8.35, p < 0.001) with a main effect of drug treatment SART.S23506 (F(2, 171.77) = 9.94, p < 0.001). Overall, AM3506 reduced NREM gamma (t(155.32) = -3.45, p = 0.001), and relative to vehicle, AM3506 specifically reduced NREM gamma across the first 18 Hr of the experiment (ZT 12?6: t(170.04) -2.42, p 0.033). F, REM epochs. Left panel: No effect of AM3506 on REM delta power. Middle panel: For REM theta, there was a significant overall interaction (drug x time of day within photoperiod, F(12, 157.56) = 1.96, p = 0.031) with a main effect of photoperiod (F(1, 104.31) = 6.78, p = 0.011). Compared to vehicle, REM theta was increased during the first 3 Hr immediately following administration of AM3506 (t(63.88) = 3.17, p = 0.005). Right j.jebo.2013.04.005 panel: For REM gamma power, there was an overall interaction (drug x time of day within photoperiod,PLOS ONE | DOI:10.1371/journal.pone.0152473 March 31,37 /Endocannabinoid Signaling Regulates Sleep StabilityF(12, 166.38) = 2.09, p = 0.020), a secondary interaction (drug x photoperiod, F(2, 172.23) = 3.29, p = 0.039) with main effects of drug (F(2, 148.36) = 8.64, p < 0.001) and photoperiod (F(1, 146.71) = 19.90, p < 0.001). Overall, REM gamma power was reduced following AM3506 administration (t(125.06) = -2.67, p = 0.017) with specific reduction in REM gamma during the first 9 Hr of the experiment (ZT 12?1: t(143.63) -3.10, p 0.005). Symbols/Bars represent mean EM for 3 Hr time bins (N = 9). Grey background in graphs shows dark photoperiod. Asterisks denote significant difference from vehicle baseline. All injections administered at onset of dark photoperiod (ZT 12:00). (PDF) S8 Fig. Power Spectral Features of EEG are Altered by Administration of the CB1 Antagonist AM281 Before the Dark Photoperiod. A--C, Po.